BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

 SAN CARLOS, Calif. 

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment

BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment

(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies.

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said:

“BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forward. At EHA, tacabrutideg is showing durable responses in heavily pretreated CLL, where patients have limited options, with early data suggesting potential in earlier lines of treatment. At the same time, the depth and consistency of responses we’re seeing with our ZS combination supports its potential to become the foundation of time-limited therapy, bringing us closer to a future where durable, treatment-free remission is possible. Together, these data reflect our ambition to define the next era of care in B-cell malignancies.”

Updated CaDAnCe-101 data show durable responses with tacabrutideg in heavily pretreated R/R CLL/SLL and R/R WM (Oral Presentation: S152; June 14, 11:00 AM-12:15 PM CEST; Poster Presentation: PS2033; June 13, 2026, 6:45-7:45 PM CEST)

The oral presentation, which was selected for inclusion in the EHA Press Program, will highlight data from 67 patients with R/R CLL/SLL treated with tacabrutideg across the different dose levels (50-500 mg), including patients with high-risk disease features (del(17p)/TP53 mutation, unmutated IGHV, complex karyotype, and BTK inhibitor resistance mutations). With a median study follow-up of 25.4 (range, 0.3-40.1) months, the analysis showed:

Overall response rate (ORR): 85.1%

Median time to first response (TTFR): 2.8 months (range, 2.0-19.4)

Median duration of response (DOR): 20.7 months (range, 0-27.6)

24-month progression-free survival (PFS) rate: 53.8% (95% CI, 38.8%-66.6%)

Safety: tacabrutideg was generally well tolerated in this heavily pretreated population with no treatment-related deaths and no new toxicities identified; patients with treatment response had rapid and sustained cytopenia improvement

In patients with R/R Waldenstrom macroglobulinemia (WM), tacabrutideg showed substantial responses in heavily pretreated patients, including those bearing BTK, CXCR4, and TP53 mutations, with major response rate (MRR) of 76.3% and very good partial response (VGPR) of 30.2% and a 15-month PFS rate of 70.4% (95% CI, 52.6-82.5) at a median PFS follow-up of 16.6 months.

Stephan Stilgenbauer, Professor of Medicine and Medical Director of the Comprehensive Cancer Center Ulm (CCCU), Head of the Early Clinical Trials Unit (ECTU), and Head of the Division of CLL Dept. of Internal Medicine III at Ulm University, said:

“Once patients with relapsed or refractory CLL progress after both BTK and BCL2 inhibitors, treatment options become extremely limited. In this study, tacabrutideg, which is designed to degrade BTK rather than inhibit it, achieved durable responses even in patients with high-risk clinical and biological characteristics, such as resistance mutations. These findings suggest a promising new approach for patients who currently have few effective therapies available.”

First report of tacabrutideg in BTK inhibitor–naïve patients shows potential for improved efficacy in earlier treatment lines (Poster Presentation: PS1693; June 13, 2026, 6:45-7:45 PM CEST)

In the first clinical evaluation of tacabrutideg in patients who had not previously received a BTK inhibitor (N=54; CLL/SLL, n=29; mantle cell lymphoma [MCL], n=8; marginal zone lymphoma, n=10; Richter transformation, n=2; WM, n=5), tacabrutideg was well tolerated and showed promising and rapid antitumor activity. In 22 evaluable patients with CLL/SLL with median follow-up of 8.2 (range: 0.4-12.8) months, the study shows:

ORR: 86.4% Median TTFR: 2.8 (range, 2.7-5.6) months

At 6 months, none of the patients had progressed

Safety: tacabrutideg was generally well tolerated with no reported opportunistic infections, major hemorrhage or febrile neutropenia

Rapid, deep, and durable responses with ZS reinforce the potential to redefine time-limited treatment across CLL and MCL (Multiple Presentations)

Across multiple presentations at EHA 2026, the all-oral ZS combination demonstrated rapid, deep, and durable responses across both treatment-naïve and relapsed/refractory settings. These data highlight the ability of ZS to drive high rates of undetectable minimal residual disease (uMRD) and sustained disease control regardless of risk factors reinforcing its potential to redefine expectations for fixed-duration, time-limited therapy in B-cell malignancies.

In treatment-naïve CLL (Oral Presentation: S145; June 12, 2026; 5:15-6:30 PM CEST):

ORR: 100%, with complete responses in 59.5% of patients

Best uMRD4 rate: 98.8%

No patient that achieved uMRD4 reverted to uMRD positivity

Best uMRD in patients with TP53 mutation/del(17p): 92.9% across 2 dose levels

Median time from combination start to uMRD4: 4.5 months

At a median follow-up of 34.1 months, no disease progression events were observed at the recommended Phase 2 dose of 320mg, including patients who electively discontinued therapy

In R/R CLL (Poster Presentation: PS1697; June 13, 2026, 6:45-7:45 PM CEST), at the 320mg (RP2D) of sonrotoclax:

ORR: 100%, with complete responses in 52% of patients

Best uMRD4 rate: 85%

No patient that achieved uMRD4 reverted to uMRD positivity

36-month PFS: 95.5% (95% CI, 83.2%-98.9%) across all dose cohorts at a median follow-up of 40.6 months (range, 10.2-60.6 months)

In R/R MCL (Poster Presentation: PF933; June 12, 2026, 6:45-7:45 PM CEST), at the 320mg (RP2D) of sonrotoclax:

ORR: 82%, with complete responses in 59% of patients

Median duration of response (DOR): not reached

30-mo DOR: 78.3% (95% CI, 51.3.%-91.4%)

About Tacabrutideg (BGB-16673)

With first-in-class and best-in-class potential, tacabrutideg is a foundational, orally administered Bruton’s tyrosine kinase (BTK) degrader. Tacabrutideg is the most advanced BTK degrader in the clinic with 1,200+ patients dosed to date in an extensive global clinical development program. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, tacabrutideg is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.

The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to tacabrutideg for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted tacabrutideg PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.

About BEQALZI™ (sonrotoclax)

BEQALZI™ (bee-KAHL-zee; sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. Sonrotoclax has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,500 patients have been enrolled across the broad sonrotoclax global development program.

BEQALZI is approved by the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a BTK inhibitor. It is also approved in China for adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy, including a BTK inhibitor.

About BRUKINSA® (zanubrutinib)

BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.

With the broadest label globally, BRUKINSA is the foundational BTK inhibitor and is the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing.

The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.

Select Important Safety Information for BEQALZITM (sonrotoclax)

Serious and sometimes fatal adverse reactions have occurred with BEQALZI, including tumor lysis syndrome (TLS), serious infections, neutropenia, and embryo-fetal toxicity. BEQALZI is contraindicated with strong CYP3A inhibitors at initiation and during the ramp-up phase due to the potential for an increased risk of tumor lysis syndrome.

In the safety population (N=115), tumor lysis syndrome occurred in 7% of patients who followed the recommended dose ramp-up. Serious infections occurred in 14% of patients, and Grade 3 or 4 infections occurred in 17% (fatal: 2.6%), with pneumonia (10%) being the most common Grade 3 or greater infection. Grade 3 or 4 decreases in neutrophils occurred in 18% of patients (Grade 4: 6%), and febrile neutropenia occurred in 1.7% of all patients. The most common adverse reactions (≥15%) were pneumonia (16%) and fatigue (16%). The most common Grade 3–4 laboratory abnormalities (≥15%) were decreases in lymphocytes (29%) and neutrophils (18%).

Please see full Prescribing Information.

Select Important Safety Information for BRUKINSA

Serious adverse reactions, including fatal events, have occurred with BRUKINSA, including hemorrhage, infections, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity (including drug-induced liver injury).

In the pooled safety population (N=1729), the most common adverse reactions (≥30%), including laboratory abnormalities, in patients who received BRUKINSA were neutrophil count decreased (51%), platelet count decreased (41%), upper respiratory tract infection (38%), hemorrhage (32%), and musculoskeletal pain (31%).

Please see full U.S. Prescribing Information including U.S. Patient Information.

The information provided in this press release is intended for a global audience. Product indications vary by region.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of tacabrutideg and Z+S combination; Z+S combination’s potential to become the foundation of time-limited therapy; BeOne’s ambition to define the next era of care in B-cell malignancies; clinical development plans of BeOne’s product candidates;; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260612883951/en/

Permalink

https://www.aetoswire.com/en/news/1206202655651

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+ 1 667-351-5176

media@beonemed.com

Venture Global and Atlantic-SEE Announce Expansion of Long-Term LNG Sales and Purchase Agreement with Greece

 Deal doubles quantity of US LNG to be supplied by Venture Global, expanding existing partnership to bolster Central and Eastern European energy security

Builds on Venture Global’s regasification capacity investment in the Alexandroupolis LNG import terminal to supply U.S. LNG to the region

 

(BUSINESS WIRE)--Today, Venture Global, Inc. (NYSE: VG) and ATLANTIC – SEE LNG TRADE S.A. of Greece announced an expansion of their existing Sales and Purchase Agreement (SPA) for the purchase of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. Under the deal, Atlantic-SEE is doubling their existing contract with Venture Global from a minimum of 0.5 million tonnes per annum (MTPA) to 1.0 million tonnes per annum (MTPA).

Atlantic-SEE LNG is a newly formed joint venture announced in November at the 6th Partnership for Transatlantic Energy Cooperation (PTEC) conference hosted in Athens, Greece between Greek companies AKTOR Group and DEPA Commercial. The announcement of this expanded supply agreement follows Venture Global’s previously announced investment in regasification capacity at the Alexandroupolis LNG import terminal in Greece, which currently accounts for approximately 25% of the terminal’s total capacity. The Alexandroupolis LNG FSRU receiving terminal and South-North ‘Vertical Corridor’ will be essential to enhancing Central and Eastern European energy security by providing a new route to bring affordable and reliable U.S. natural gas into the region.

“Venture Global is honored to announce this expanded partnership which reinforces our shared commitment to energy security, supply diversification, and economic growth, while advancing the strategic energy relationship between the United States and Europe,” said Venture Global CEO Mike Sabel. “The Vertical Corridor has emerged as a vital energy hub for the region, and our continued investment in infrastructure such as the Alexandroupolis terminal is helping create new pathways for secure, reliable energy supply across Central and Eastern Europe. We are grateful for the leadership of President Trump, Secretary Burgum, Secretary Wright, Ambassador Guilfoyle, and officials across both sides of the Atlantic whose support continues to strengthen transatlantic energy cooperation and expand access to U.S. LNG around the world.”

“The expansion of our commercial agreement with Venture Global reflects the ambition and solid ground of our long-term strategic plan on LNG and the potential of the vertical corridor, which can provide alternatives and energy security across Central and Eastern Europe. It also highlights the growing importance of the transatlantic energy cooperation between Greece and the United States that will benefit the entire region,” said Alexandros Exarchou, CEO of Atlantic SEE LNG Trade. “The geopolitical development has offered us the historic opportunity to operate as an energy hub between continents, and we aspire to build on this momentum and offer our customers long-term, sustainable, and predictable energy safety.”

“Today’s agreement marks the successful transition from vision to action," said Konstantinos Xifaras, Chairman of Atlantic SEE LNG Trade. “By doubling the volumes secured under this agreement, we are creating a stronger foundation for reliable and predictable LNG supplies across the region, while translating strategic planning into concrete commercial outcomes. This agreement reflects the value of long-term partnerships and reinforces the growing role of transatlantic energy cooperation in supporting regional energy security and resilience.”

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

About Atlantic SEE LNG Trade

ATLANTIC – SEE LNG TRADE is a company in which AKTOR Group of Companies holds a 60% stake and DEPA Commercial holds 40%, respectively. Its goal is to import Liquefied Natural Gas (LNG) into Greece and trade it across Eastern and Southeastern Europe via the Vertical Energy Corridor, thereby contributing to Europe's energy supply security and strengthening Transatlantic Cooperation.

Forward-looking Statements

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical facts, included herein are “forward-looking statements.” In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.

These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include statements about our future performance, our contracts, our anticipated growth strategies and anticipated trends impacting our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include our need for significant additional capital to construct and complete future projects and related assets, and our potential inability to secure such financing on acceptable terms, or at all; our potential inability to accurately estimate costs for our projects, and the risk that the construction and operations of natural gas pipelines and pipeline connections for our projects suffer cost overruns and delays related to obtaining regulatory approvals, development risks, labor costs, unavailability of skilled workers, operational hazards and other risks; the uncertainty regarding the future of global trade dynamics, international trade agreements and the United States’ position on international trade, including the effects of tariffs; our dependence on our EPC and other contractors for the successful completion of our projects, including the potential inability of our contractors to perform their obligations under their contracts; various economic and political factors, including opposition by environmental or other public interest groups, or the lack of local government and community support required for our projects, which could negatively affect the permitting status, timing or overall development, construction and operation of our projects; and risks related to other factors discussed under “Item 1A.—Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (“SEC”) and any subsequent reports filed with the SEC.

Any forward-looking statements contained herein speak only as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements to reflect subsequent events or circumstances, except as may be required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611230438/en/

Permalink

https://www.aetoswire.com/en/news/1206202655636

Contacts

Investor contact:

Ben Nolan

IR@ventureglobalLNG.com

Media contact:

Shaylyn Hynes

press@ventureglobalLNG.com

 

NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer

TOKYO - Friday, 12. June 2026

Kazuhiko Nakayama appointed President and CEO of NTT DATA Group; Yutaka Sasaki to become Senior Executive Vice President of NTT, Inc.

 

(BUSINESS WIRE)--NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18.

Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates.

NTT DATA Group’s growth strategy will focus on two key areas alongside its core business operations: AI‑empowered New Value & Productivity; and Next‑Generation Infrastructure. It aims to lead in areas such as Operational AI, which supports business transformation, and Physical AI, which enables the application of AI in physical spaces such as worksites and facilities.

Nakayama began his career at NTT in 1989 and has since made significant contributions to NTT DOCOMO, NTT EAST, and NTT Communications. He was appointed to the role of CFO of NTT DATA Group in 2023. Prior to that role, Nakayama was Senior Vice President & Head of Finance and Accounting at NTT. He holds a master's degree in business administration from Harvard University, and a bachelor's degree in economics from The University of Tokyo.

Kazuhiko Nakayama, President and CEO, NTT DATA Group commented:

“Over the past three years I have had the honour of working closely with Mr Sasaki and the leadership team on a strategic course that has established NTT DATA among the top five IT services businesses globally. That experience has reinforced my conviction in the strength of our offering, the quality of our people and the size of the opportunity ahead. As I take on the responsibilities of CEO and lead the growth of the NTT DATA Group going forward, I feel a deep sense of dedication, possibility and excitement.”

Yutaka Sasaki, outgoing President and CEO, NTT DATA Group, and Senior Executive Vice President of NTT, Inc. Elect commented:

“The appointment of Mr Nakayama as President and Chief Executive Officer follows a thoughtful and carefully planned succession process. Under the leadership of Mr Nakayama, NTT DATA Group will embark on a new management structure. NTT DATA Group stands at the very core of the NTT Group and serves as its growth engine. Under Mr Nakayama’s renewed growth strategy, I look forward to seeing continued strength in performance and a commitment to achieving quality growth together as One NTT DATA.”

Further details regarding NTT DATA Group Corporation's new executive leadership team, decided by resolution of the Board of Directors on June 12, 2026, can be found here.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world's leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.

Visit us at nttdata.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611471845/en/

Permalink
https://www.aetoswire.com/en/news/1206202655640

Contacts

For more information, please contact
NTT DATA Group Corporation
Global Marketing & Communications Headquarters
global-marketing@kits.nttdata.co.jp

Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes

 ARLINGTON, Va. - Friday, 12. June 2026 AETOSWire Print 

(BUSINESS WIRE)--Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption.

The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amounts of indebtedness will also guarantee the Notes, except during any period where the Notes are rated investment grade by specified rating agencies (the “Suspension Period”). The Notes and any future guarantees of the Notes will be secured on a first-priority basis by the same lien on the collateral that secures the Issuer’s existing notes and revolving credit facility, subject to certain liens permitted under the indenture that will govern the Notes. The Notes will cease to be secured during any Suspension Period.

The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements included herein that are not statements of historical facts are “forward-looking statements.” In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.

These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, expectations regarding the development, construction, commissioning and completion of our projects, expectations regarding sales of LNG cargos, estimates of the cost of our projects and schedule to construct and commission our projects, our anticipated growth strategies and anticipated trends impacting our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including: our potential inability to maintain profitability, maintain positive operating cash flow and ensure adequate liquidity in the future, including as a result of the significant uncertainty in our ability to generate proceeds and the amount of proceeds that will regularly be received from sales of uncontracted commissioning cargos and excess cargos due to volatility and variability in the LNG markets; our need for significant additional capital to construct and complete projects, including some of our existing projects, future projects, potential bolt-on expansions and related assets, and our potential inability to secure such financing on acceptable terms, or at all; our potential inability to construct or operate all of our proposed LNG facilities or pipelines or any additional LNG facilities or pipelines beyond those currently planned, including any of the bolt-on expansion opportunities which we have identified, and to produce LNG in excess of our nameplate capacity, which could limit our growth prospects, including as a result of delays in obtaining regulatory approvals or inability to obtain requisite regulatory approvals to complete construction during our estimated development periods; significant operational risks related to our natural gas liquefaction and export projects, including the our existing projects and any potential bolt-on expansions, any future projects we develop, our pipelines, our LNG tankers, and our regasification terminal usage rights; our potential inability to accurately estimate costs for our projects, and the risk that the construction and operations of natural gas pipelines and pipeline connections for our projects suffer cost overruns and delays related to obtaining regulatory approvals, development risks, labor costs, unavailability of skilled workers, operational hazards and other risks; the uncertainty regarding the future of international trade agreements and the United States’ position on international trade, including the effects of tariffs as well as the effects of ongoing legal challenges to tariffs and reimbursements of tariffs; our current and potential involvement in disputes and legal proceedings, including the arbitrations and other proceedings currently pending against us and the possibility and magnitude of negative outcomes in any such dispute or proceeding and the potential impact thereof on our results of operations, liquidity and our existing contracts; our potential inability to enter into the necessary contracts to construct our projects, or any potential bolt-on expansion, on a timely basis or on terms that are acceptable to us; our potential inability to enter into Contracted SPAs with customers for, or to otherwise sell, an adequate portion of the total expected nameplate capacity at our projects, or any potential bolt-on expansion, or any future projects we develop; our dependence on our EPC contractors and suppliers for the successful completion of our projects and delivery of our LNG tankers, including the potential inability of our contractors to perform their obligations under their contracts; various economic and political factors, including opposition by environmental or other public interest groups, or the lack of local government and community support required for our projects, which could negatively affect the permitting status, timing or overall development, construction and operation of our projects; the effects of FERC regulation on our interstate natural gas pipelines and their FERC gas tariffs; the risk that the natural gas liquefaction system and mid-scale design we utilize at our projects will not achieve the level of performance or other benefits that we anticipate; potential additional risks arising from the duration of and the phased commissioning start-up of our projects; the potential risk that our customers or we may terminate our SPAs if certain conditions are not met or for other reasons; potential decreases in the price of natural gas and its related impact on our ability to pay the cost of gas transportation, the payment of a premium by us for feed gas relative to the contractual price we charge our customers, or other impacts to the price of natural gas resulting from inflationary pressures, including from the disruption in international oil and natural gas supply chains caused by the ongoing war in Iran and the closure of the Strait of Hormuz; the potential negative impacts of seasonal fluctuations on our business; the risks related to the development and/or contracting for additional gas transportation capacity to support the operation and expansion capacity of our LNG projects; the risks related to the management and operation of our LNG tanker fleet and our future regasification terminal usage rights; the potential effects of existing and future environmental and similar laws and governmental regulations on compliance costs, operating and/or construction costs and restrictions; our potential inability to obtain, maintain or comply with necessary permits or approvals from governmental and regulatory agencies on which the construction of our projects depends, including as a result of opposition by environmental and other public interest groups; our indebtedness levels, and the fact that we may be able to incur substantially more indebtedness, which may increase the risks created by our substantial indebtedness. For more information on these and other factors that could cause our results to differ materially from expected results, please refer to the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2025. In addition, please note that the date of this press release is June 11, 2026, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements as a result of new information or future events.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611109916/en/

Permalink

https://www.aetoswire.com/en/news/1206202655638

Contacts

Investor Contact:

Ben Nolan

IR@ventureglobalLNG.com

Media Contact:

Shaylyn Hynes

press@ventureglobalLNG.com

Visa Announces New AI, Stablecoin and Token Innovations to Power Intelligent, Programmable Commerce at Visa Payments Forum

 New Agent Scoring, Agentic Registry and Large Transaction Model capabilities, stablecoin settlement and token enhancements support the next gen of digital commerce

 

(BUSINESS WIRE)--At Visa Payments Forum 2026, Visa (NYSE: V) today announced new AI, stablecoin and token capabilities designed to help clients unlock the next generation of commerce. These innovations reflect a simple objective: ensuring trust, security and control evolve alongside increasingly fast, automated and intelligent commerce experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610464331/en/

In a keynote presentation, Jack Forestell, Chief Product & Strategy Officer at Visa, outlined how two foundational shifts—artificial intelligence and stablecoins—are transforming both the front end and back end of money movement, and how Visa is enabling clients to participate.

“AI is transforming the front end of commerce. Stablecoins are reshaping the back end,” said Forestell. “Visa’s role is to enable it to work securely, reliably and at global scale, for every participant in the ecosystem.”

Powering the Front End of Commerce—and How It Gets Built—with AI

Visa detailed how AI is reshaping how transactions are initiated, authorized and trusted—while also accelerating how new commerce experiences are designed, developed and delivered, particularly as AI agents increasingly act on behalf of consumers and businesses.

Visa Intelligent Commerce, the company’s platform for agentic commerce, provides the trust, controls and connectivity needed for AI agents to securely discover, initiate and complete transactions.

To support this shift, Visa is working across the ecosystem—partnering with leading AI platforms, enabling new merchant capabilities and building infrastructure to ensure agent-initiated transactions are transparent and trusted, including:

Agent Score: Created with New Generation, it allows merchants to evaluate their websites for agentic commerce readiness—specifically, whether AI agents can navigate, understand and complete tasks on a merchant’s website.

Agentic Directory: Merchants need to know which agents can be trusted to transact on their sites, and agents need confidence that they are interacting with legitimate merchants. The directory includes agents and merchants that Visa has verified as legitimate participants in agentic commerce.

OpenAI Partnership: a strategic collaboration with OpenAI to enable secure Visa payments within agentic commerce, enabling seamless and trusted payments across OpenAI. Through the partnership, Visa will provide its global network, credentialing capabilities and security infrastructure to support agentic commerce experiences, helping consumers and businesses interact and transact with confidence.

Large Transaction Model: An AI model trained on billions of transactions to improve fraud detection while increasing authorization performance and reducing false declines—a trade-off the industry has struggled with for years.

Visa also demonstrated early development concepts from its Crypto Labs and developer teams. This included a Command Line Interface proof of concept that lets AI agents pay for digital services directly in the terminal using Visa’s tokenized credentials.

“We believe a growing share of creation and transactions will be led by developers using AI tools,” said Forestell. “We are working with the industry to make cards the best way to pay in the Command Line.”

Enhancing Tokens for AI-Driven Commerce

Visa announced significant enhancements to its tokens, focused on bringing more data, context and assurance into the credentials used in digital commerce.

Today, tokens already carry a highly secure data set purpose-built for digital payments. As commerce extends to new channels and agents, Visa is enriching the data to provide more details on the transaction type, where the token is being used and who is making the payment.

A second key advancement is a token assurance signal. Token use is evaluated throughout its lifecycle—based on provisioning and behavioral history—to generate a signal of trust behind each transaction.

These enhancements provide issuers with stronger signals for authorization decisions, helping reduce false declines for merchants while minimizing friction for consumers.

Designed for AI-driven commerce, these developments embed identity, permissions and behavioral signals more deeply into credentials—allowing trust to travel with the transaction across devices, channels and use cases, including those initiated autonomously by AI agents.

Modernizing the Back End of Money Movement with Stablecoins

Visa also shared progress in modernizing settlement and value transfer through stablecoins and blockchain-based infrastructure.

Tokenized Deposits: Visa announced it will build the technology layer that can allow banks to turn traditional deposits into programmable, always-on digital money. This gives banks a way to match the speed and flexibility of stablecoins while keeping funds on balance sheet.

Stablecoin Settlement: Visa is expanding stablecoin settlement pilots across multiple regions, blockchains and currencies. Building on its first stablecoin settlement pilots in early 2025, Visa has moved billions of dollars in stablecoins across VisaNet, with an annualized run rate of approximately $7 billion as of March 2026. With issuing banks already settling seven days a week onchain with Visa, Visa is also working to extend seven-day settlement to include acquirers, increasing flexibility and frequency across the entire ecosystem.

Stablecoin-Linked Cards: Visa continues to expand stablecoin-linked card programs, enabling consumers and businesses to spend stablecoin balances anywhere Visa is accepted. With more than 160 programs live or in development globally, adoption is expected to accelerate.

Helping Clients Modernize Without Disruption

Across these innovations, Visa emphasized a consistent theme from clients: modernization is essential, but full system replacement is not practical. Visa is addressing this with modular, cloud-native capabilities that integrate with existing infrastructure and enable banks, fintechs, acquirers and merchants to modernize at their own pace.

For issuers, the Pismo core banking platform enables flexible, real-time banking and processing capabilities with a phased path away from traditional systems.

For acquirers and merchants, Unified Checkout provides a consistent way to accept both card and non-card payments through a single orchestration layer—supporting evolving commerce models, including AI-driven transactions. Visa Intelligent Authorization uses real-time network signals and advanced models to help acquirers and their merchants optimize authorization approvals and capture incremental spend that might otherwise be declined.

Leading the Evolution of Commerce

Taken together, the announcements at Visa Payments Forum reflect a clear vision: Visa is becoming the platform that connects AI, programmable money, modern infrastructure and global trust so clients can win now and be ready for what’s next.

“History is filled with innovations that never reached scale,” said Forestell. “What determines success is trust, security and global reach. That’s what Visa brings to every new era of commerce – and what we’re building for the future.”

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610464331/en/

Permalink

https://aetoswire.com/en/news/1106202655580

Contacts

Media Contacts

Conor Febos - press@visa.com

Jackie Dresch - press@visa.com

 

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

 

VICTORIA, Seychelles - Thursday, 11. June 2026

(GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange, has expanded its stock spot lineup with the listing of 30 new stock spot assets, further widening users’ access to traditional market opportunities under the recent launch of Stock 2.0. The newly listed assets include rNASA, rBMNR, rDIS, rROKU, and rLCID, and were made available on June 8, 2026.

The latest additions cover a diverse range of companies and investment themes, spanning space innovation, entertainment, consumer brands, enterprise technology, healthcare, defense, cloud infrastructure, education technology, and electric vehicles. The newly supported assets include Tema Space Innovators ETF, BitMine Immersion Technologies, AbbVie, Automatic Data Processing, BlackSky Technology, BWX Technologies, CAVA Group, Celsius Holdings, Cognex, CRISPR Therapeutics, The Walt Disney Company, DigitalOcean, Duolingo, Guidewire Software, Himax Technologies, Hewlett Packard Enterprise, The Coca-Cola Company, Lucid Group, and Lockheed Martin, among others.

Following the recent integration of 49 U.S. equities and ETFs, as well as the expansion of the Bitget Unified Trading Account to include tokenized stocks as margin assets, this latest update provides users with even broader exposure to established global corporations and emerging growth companies across high-activity market sectors. Bitget enhances the accessibility of traditional financial products alongside its robust crypto and market instrument suites, enabling a more comprehensive investment experience through a single, unified platform.

The addition further strengthens Bitget's Universal Exchange strategy, which brings together crypto assets, stocks, ETFs, commodities, foreign exchange products, precious metals, derivatives, and tokenized financial instruments within a unified trading environment. The platform currently offers access to more than 100 tokenized stocks and ETFs, alongside a growing suite of traditional financial products designed to help users navigate opportunities across global markets.

For more information, visit here.

About Bitget

 

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Contacts :

For media inquiries, please contact: media@bitget.com

Andersen Consulting Strengthens Digital Transformation and Cybersecurity Offerings with HeadMind Partners

 (BUSINESS WIRE)--Andersen Consulting enters into a Collaboration Agreement with HeadMind Partners, a leading European consultancy specializing in cybersecurity, digital transformation, and AI, strengthening the organization’s platform.

With its unique combination of 25 years’ business experience, technology and data expertise, HeadMind Partners enables its clients, large companies from both private and public sectors, to strengthen their digital and cyber resilience, enhance their operational efficiency, and build robust and sovereign AI solutions. Headquartered in Paris and operating in France and Belgium to date, the company draws on multidisciplinary teams of 500 cybersecurity experts, 70 AI engineers and 400 digital transformation specialists to provide value-creating and seamless cybersecurity, AI and digital transformation solutions. HeadMind Partners serves a diverse and renowned client portfolio across financial services, industry, energy, luxury and the public sector.

“Collaborating with Andersen Consulting connects us to a truly global organization,” said Guy-Hubert Bourgeois, chairman and CEO of HeadMind Partners. “By integrating our cybersecurity, AI, and digital-program solutions with Andersen’s global platform, we look forward to leveraging synergies with the member and collaborating firms to continuously elevate a client offering designed to deliver sustained value.”

“Our collaboration with HeadMind enhances our ability to address the growing digital, cyber, and operational challenges facing our clients,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “HeadMind’s depth in these areas strengthens our global capabilities and supports our commitment to delivering seamless, integrated consulting services across markets and industries.”

Andersen Consulting is a global consulting practice providing a comprehensive suite of services spanning corporate strategy, business, technology, and AI transformation, as well as human capital solutions. Andersen Consulting integrates with the multidimensional service model of Andersen Global, delivering world-class consulting, tax, legal, valuation, global mobility, and advisory expertise on a global platform with more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms. Andersen Consulting Holdings LP is a limited partnership and provides consulting solutions through its member firms and collaborating firms around the world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611951863/en/

Permalink

https://www.aetoswire.com/en/news/1106202655617

Contacts

mediainquiries@Andersen.com